Evidence map›Paper›PMID 41513931›Full record

ReviewJournal of cancer survivorship : research and practice2026

Mapping advanced and metastatic cancer survivorship research in Australia: a systematic scoping review.

Andrea L Smith, Philip Ly, Holly Keogh, Isabel Rewais, Molly Valencour, Qian Wang, Nicolas H Hart, Carolyn Mazariego, Larissa Nekhlyudov

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of cancer survivorship : research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Andrea L SmithThe Daffodil Centre, The University of Sydney, and Cancer Council NSW, Sydney, NSW, Australia. andrea.smith@sydney.edu.au.ORCID http://orcid.org/0000-0002-9194-4888
Philip LyThe Daffodil Centre, The University of Sydney, and Cancer Council NSW, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0002-9828-6750
Holly KeoghSydney School of Public Health, The University of Sydney, Sydney, NSW, Australia.ORCID http://orcid.org/0009-0004-6804-7611
Isabel RewaisThe Daffodil Centre, The University of Sydney, and Cancer Council NSW, Sydney, NSW, Australia.ORCID http://orcid.org/0009-0005-4555-3439
Molly ValencourSydney School of Public Health, The University of Sydney, Sydney, NSW, Australia.ORCID http://orcid.org/0009-0005-1984-3336
Qian WangThe Daffodil Centre, The University of Sydney, and Cancer Council NSW, Sydney, NSW, Australia.ORCID http://orcid.org/0009-0002-2343-6950
Nicolas H HartHuman Performance Research Centre, INSIGHT Research Institute, Faculty of Health, University of Technology Sydney, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0003-2794-0193
Carolyn MazariegoSchool of Population Health, University of New South Wales, Randwick, NSW, Australia.ORCID http://orcid.org/0000-0003-3965-4960
Larissa NekhlyudovDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6747-4209

Funding

Cancer Institute NSW 024/ECF1482National Health and Medical Research Council APP2017080University of Sydney Daffodil Fellowship
6 · The paper itself

Abstract

purposeTo map advanced and metastatic cancer survivorship research in Australia and characterize studies according to the priority research themes outlined by the US National Cancer Institute (NCI).

methodsSystematic scoping review. MEDLINE, PsycINFO, Embase and CINAHL were searched from inception to December 2024 for cancer survivorship studies conducted in Australia, with studies reporting data for people with advanced or metastatic cancer classified using NCI's priority research themes.

resultsWe identified 483 studies, of which 72 (14.9%) recruited and reported data for participants with advanced or metastatic cancer, focusing on: psychosocial research (51.4%); healthcare delivery (16.7%); health behaviors (12.5%); symptom management (11.1%); and epidemiology and surveillance (8.3%). Most were conducted within individual Australian states (72.2%) and involved multiple cancer types (41.7%). Study designs included qualitative (44.4%), cross-sectional (34.7%), cohort (16.7%), case-control (1.4%), case report (1.4%) and mixed methods (1.4%). Forty-two tumor-specific studies were identified including breast (33.3%), hematological (21.4%); prostate (11.9%); bowel/colorectal (11.9%), gynecological (9.5%), melanoma (7.1%), head and neck (2.4%), and lung (2.4%) cancers. Nearly a quarter of studies recruited participants via cancer registries (22.2%).

conclusionsFew cancer survivorship studies included people with advanced or metastatic cancer in Australia. We offer six recommendations to support funders, clinicians, policymakers, and researchers to improve representation of advanced or metastatic cancer survivors in survivorship research programs. Similar efforts in other countries are needed. IMPLICATIONS FOR CANCER SURVIVORS: Increasing numbers of people are living long-term with advanced or metastatic cancer. The purposeful inclusion of these people in cancer survivorship research and care programs will improve health outcomes.

Indexed as

Advanced cancerAustraliaCancer survivorshipMetastatic cancerMetastatic survivorship

Identifiers

PMID41513931

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.